Jean Francois Formela Sells 48,438 Shares of Korro Bio (NASDAQ:KRRO) Stock

Posted by George Bondi on Jun 24th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Francois Formela sold 48,438 shares of Korro Bio stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $14.61, for a total value of $707,679.18. Following the transaction, the director owned 169,556 shares in the company, valued at approximately $2,477,213.16. This represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Francois Formela also recently made the following trade(s):

On Tuesday, June 23rd, Jean Francois Formela sold 119,005 shares of Korro Bio stock. The shares were sold at an average price of $14.25, for a total value of $1,695,821.25.
On Monday, June 22nd, Jean Francois Formela sold 3,962 shares of Korro Bio stock. The stock was sold at an average price of $13.95, for a total value of $55,269.90.
On Thursday, May 28th, Jean Francois Formela sold 2,860 shares of Korro Bio stock. The stock was sold at an average price of $13.95, for a total value of $39,897.00.

Korro Bio Trading Up 0.4%

Shares of NASDAQ KRRO traded up $0.06 during mid-day trading on Wednesday, reaching $13.77. 448,896 shares of the company’s stock were exchanged, compared to its average volume of 200,441. Korro Bio, Inc. has a twelve month low of $5.20 and a twelve month high of $55.89. The firm has a market capitalization of $198.56 million, a price-to-earnings ratio of -1.18 and a beta of 3.00. The business has a fifty day simple moving average of $12.20 and a 200 day simple moving average of $11.14.

Korro Bio (NASDAQ:KRRO – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%. Equities research analysts predict that Korro Bio, Inc. will post -5.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently bought and sold shares of KRRO. Affinity Asset Advisors LLC bought a new position in shares of Korro Bio during the 1st quarter worth approximately $8,002,000. Nantahala Capital Management LLC acquired a new position in Korro Bio during the fourth quarter worth $4,806,000. ADAR1 Capital Management LLC acquired a new position in Korro Bio during the first quarter worth $6,113,000. TCG Crossover Management LLC bought a new position in Korro Bio in the third quarter valued at $19,937,000. Finally, JPMorgan Chase & Co. grew its position in Korro Bio by 6,185.5% in the third quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock valued at $9,542,000 after purchasing an additional 196,079 shares in the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on KRRO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Wednesday, April 8th. Citigroup initiated coverage on shares of Korro Bio in a research report on Monday, May 18th. They issued a “buy” rating and a $21.00 price objective on the stock. Raymond James Financial raised shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Friday, March 13th. Wall Street Zen raised Korro Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Lifesci Capital raised Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Check Out Our Latest Analysis on Korro Bio

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.